Copyright
©The Author(s) 2021.
World J Methodol. Jul 20, 2021; 11(4): 187-198
Published online Jul 20, 2021. doi: 10.5662/wjm.v11.i4.187
Published online Jul 20, 2021. doi: 10.5662/wjm.v11.i4.187
Table 6 Changes in clinical parameters of the included studies
| Intervention | Clinical parameters evaluated | ||||||||||
| Study | Creatinine (mg/dL) | Change in BUN (mg/dL) | Cystatin C (mg/L) | Weight loss (kg) | Urine output (mL/d) | ||||||
| Baseline | Mean changes | Baseline | Mean changes | Baseline | Mean changes | Baseline | Mean changes | Baseline | Mean changes | ||
| Tolvaptan | Inomata et al[14], 2017 | 1.5 | 0.06 ± 0.32 | NA | NA | NA | NA | 62 | -2.1 ± 1.8 | 1306 ± 494 | 459 ± 514 |
- Citation: Ong LT. Evidence based review of management of cardiorenal syndrome type 1. World J Methodol 2021; 11(4): 187-198
- URL: https://www.wjgnet.com/2222-0682/full/v11/i4/187.htm
- DOI: https://dx.doi.org/10.5662/wjm.v11.i4.187